Last updated: 2026-09-06 12:37:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
KALA BIO, Inc. (KALA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.51, with a market capitalization of $10.11M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.50 to $1,030.00. This page covers its latest market performance, valuation, price trends and company information.
$10.11M | |
$0.54 | |
$66,808.19 | |
$0.50 | |
$0.56 | |
227.63K | |
-- | |
-- | |
$1,030.00 | |
$0.50 | |
-- | |
-- |
KALA BIO, Inc. (KALA) last closed at $0.56 as of 2026-09-04 23:55:00, unchanged from the previous close of $0.56.
During the latest regular trading session, KALA traded between $0.50 and $66,808.19, with a volume of 227.63K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, KALA BIO, Inc. (KALA) moved from $0.68 to $0.51, representing a decline of 24.83% ($0.17).
The stock traded between $0.51 and $0.56 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.86 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.0%
KALA is currently trading at $0.51, placing it 0.0% of the way from its 52-week low of $0.50 to its 52-week high of $1,030.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 6 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of KALA BIO, Inc. (KALA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.